ALK+ ALCL commonly presents in young populations, generally within the first 3 decades of life and carries a significantly better prognosis (5-year OS, 70–85%) than ALK− ALCL (5-year OS, 30–49%) (48). This evidence concerns the gene ALK and anaplastic large cell lymphoma.